Objective To investigate long-term pattern of mortality in menopausal women according to different modalities of hormone therapy.
Introduction
Vasomotor symptoms such as hot flushes continue to affect a large proportion (> 70%) of women going through menopause. 1 Hormone therapy (HT) is the most effective treatment for vasomotor menopausal symptoms, 2 and before 2002, the proportion of women on HT was high. 3 However, after 2002, hormone use dropped dramatically. 4, 5 This was mainly in response to the initial reports from the large 'Women's Health Initiative' (WHI) randomised trials investigating HT as a primary health prevention, which found that the health risks associated with HT outweighed the benefits. 6 Despite finding an overall increased health risk among the women in the intervention arms, neither 9 In the most recently published Cochrane systematic review investigating the effect of HT > 1 year, only a slight increase in lung cancer-specific mortality was noted (1-8 extra cases per 1000 women on HT), but no effect on overall or other cause-specific measures of mortality was found. 10 However, the authors also note that the current evidence base is heavily dominated by the large WHI primary and HERS (Heart and Estrogen/progestin Replacement Study) secondary prevention trials. 11, 12 Even though these trials represent the highest quality evidence, the nature of their design (testing only single regimens and mainly for prevention), the fact that they were stopped early, and the demographic profile of participants (older age and existing disease), hinders a proper assessment of the impact of hormones used around menopause on long-term mortality. 10 Furthermore, considering how several risk associations seem to dissipate while others appear with longer follow up, it is relevant to analyse the distribution of events and potentially time-varying magnitude of associations during follow up in more detail. 13 Using a large population-based prospective cohort with data on hormone use collected before 2002, this study investigates the associations between hormone used around menopause and all-cause and cause-specific mortality during 20 years of follow up.
Methods

Population
The Diet, Cancer and Health Cohort is a large Danish population-based study established between 1993 and 1997. Of the 79 729 women (aged 50-64 years and without a previous cancer diagnosis) invited, 29 875 (37%) participated (corresponding to 7% of the Danish female population in the given age group). A more detailed description of the cohort has been published previously.
14 Each participant was followed from baseline (the date of first study clinic visit) until either date of death, date of emigration, or 31 December 2013, whichever came first. The Supplementary material ( Figure S1 ) gives an overview of study inclusions and exclusions, as well as the final sample distribution into different outcomes.
Measurements
Participants completed two self-administered questionnaires at baseline. Descriptions of the development and validation of the questionnaires have been published previously. 15, 16 Anthropometric measurements were obtained by professional staff members at a study clinic visit, where various biological specimens were also sampled from participants.
Exposure
In the questionnaires, the women gave information about HT (never/previous/current use) and, if relevant, the age at which they started HT. From women who indicated either previous or current hormone use, information on duration as well as route of administration (tablets/injections/skin depot/skin patch/vaginal) was used for further analysis. Women with ≤ 6 months of use were categorised as 'triers'. The route of administration was categorised as 'oral' (including any combination with others); 'other systemic' (all non-oral HT); 'only local' (only vaginal treatment). Current users also provided the brand name of the therapy they currently used. Based on these self-reported brand names, the type of HT was divided into 'estrogen alone', 'combination therapy' (estrogen and progestogen) (further subdivided into sequential or continuous regimens), or 'unspecified' if no brand name was given. Investigations from a subsample of participants including serum sex hormone measurements previously conducted in the cohort showed good correlation between self-reported HT and serum sex hormone blood levels. 17 
Outcome
Cohort members were linked via their unique national personal identification numbers to the Danish Causes of Death registry. 18 International Classification of Diseases, tenth revision (ICD-10) diagnoses for different causes of death were categorised into 'cancer' (ICD C diagnoses, and subdivided into separate types of cancer), cardiovascular disease ('CVD'; all I diagnoses), 'unknown' (R960-R999) and 'others' (all remaining recorded ICD-10 codes). Completeness of follow up on mortality was 99.6% (131/29 875 emigrated).
Covariates
The following covariates were considered as possible confounders for inclusion into the regression analyses based on a priori hypotheses of associations with the outcome.
Alcohol intake; categorised into average lifetime daily intake since age 20 using baseline age and a cumulative measure 'alcohol drinking years' (dy) [1 dy = an average of 1 unit (10 g alcohol)/day/year since age 20], and divided into six categories: 'lifetime abstainers'; minimal intake (0 dy); < 0.5 unit/day; 0.5-1 unit per day; 1-2 units/day, and > 2 units/day 
Statistical methods
The associations between HT and mortality were assessed using Cox's proportional hazards models with age as the underlying time scale, while adjusting for time of recruitment as well. We created three different models; one for each exposure parameter ('overall use'; 'type of HT used'; and 'route of administration'). 'Never users' was the reference group in all analyses. To capture the distribution of events and potentially time-varying magnitude of associations during follow up, 13 we also calculated hazard ratios (HRs) for increasingly longer periods of follow-up time (5, 10, 15 and 20 years of follow up). Competing risk regression models according to the method of Fine and Gray 20 were also performed to compare estimates in the models of cause-specific mortality, where different causes of death, at least in theory, can act as competing risks. 21 All tests were based on log likelihood ratio test statistic and confidence intervals calculated with Wald's test. All analyses were performed with STATA version 14 (StataCorp LP, TX, USA).
Ethics
The 'Diet, Cancer and Health' study has been approved by the relevant scientific committees and the Danish Data Protection Agency. Informed consent was obtained from all participants to search information from medical registers including the Danish Register of Causes of Death. 14 
Participant and public involvement
No participants were involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design or implementation of the study. No participants gave advice on interpretation or writing up of results.
Results
The characteristics of the study population and baseline hormone use are summarised in Table 1 . At baseline, 54.4% (15 904/29 243) of the women had never used hormones, 15.5% (4532/29 243) were previous users, and 30 .0% (8771/29 243) of the women currently used hormones. Among women using hormones at baseline, 2671 used estrogen alone, 1867 used combined continuous, and 3212 used combined sequential hormone preparations. Most of the women using hormones (previously or at baseline) took orally administered hormones (n = 11 559); 1147 women used a combination of oral and local therapies, and only 597 took only local hormones.
A total of 4098 participants died during a median follow up of 17.6 years (SD 2.9 years), and of these, 2155 died from cancer (222 died from colorectal cancer, 308 from breast cancer, 576 from lung cancer, 163 from ovarian cancer, 36 from endometrial cancer and another 850 from other cancers). Six hundred and seventy-one women died from CVD (203 died from ischaemic heart disease, 209 from stroke and 259 from other CVD-related causes). The remaining 1084 women died from other causes. For 188 participants, the cause of death was unknown ( Table 2 , and see Supplementary material, Figure S1 ).
After adjustment for relevant lifestyle risk factors, hormone use had no impact on all-cause mortality, regardless of type or route, at end of follow up (see Table 2 ).
When looking more closely at specific causes of death, at the end of follow up, no differences in cancer-specific mortality or mortality from other causes were seen between women on HT and never users (Table 2) . When further subdividing into death due to specific causes of cancer and specific causes of cardiovascular diseases, colorectal cancer mortality was markedly lower among both current and previous users (HR 0.64, 95% CI 0.46-0.89, and HR 0.67, 95% CI 0.46-0.99, respectively), when compared with never users (Table 3 ). This lower mortality was also seen across the remaining measures of hormone use, and statistically significant for 'oral hormone use' and 'estrogen only'. The opposite was seen for breast cancer mortality, where current users had significantly higher mortality compared with never users (HR 1.34, 95% CI 1.05-1.72). This was also seen for oral use (HR 1.29, 95% CI 1.03-1.63). The combined continuous type of HT was significantly associated with higher breast cancer mortality (HR 1.56, 95% CI 1.05-2.31), whereas the association between estrogen only and breast cancer mortality, although in the same direction, was not statistically significant (HR 1.37, 95% CI 0.95-1.98).
The category of 'only local' HT use was associated with higher risk of ischaemic heart disease as cause of death; however, there were few women in this subgroup and hence the associations were difficult to interpret. No associations were seen for other types of cancer-specific mortality or death from stroke.
Conducting a Fine and Gray competing risk regression yielded parameter estimates similar to those obtained in the Cox's regression model (see Supplementary material, Table S1B ).
During follow up, several time-varying effects of HT on cause-specific mortality were evident (Figure 1 ). There was an initially significantly lower CVD mortality among current users compared with never users (HR 0.54, 95% CI 0.32-0.92). This, however, dissipated with longer follow up (HR at 10 years: 0.78, 95% CI 0.58-1.06, and HR at 15 years: 0.92, 95% CI 0.74-1.14). Conversely, the lower colorectal cancer and higher breast cancer mortality estimates only became evident after 10 years of follow up (colorectal cancer: HR at 10 years 0.67, 95% CI 0.41-1.09; breast cancer: HR at 10 years 1.24, 95% CI 0.82-1.87), statistically significantly so after 15 years of follow up (colorectal cancer: HR at 15 years 0.65, 95% CI 0.46-0.93; breast cancer: HR at 15 years 1.33, 95% CI 1.00-1.77) (see Figure 1 ).
Discussion
Main findings
In this observational study of 29 243 Danish women, with a median age of 56 years at entry and followed up for over 17 years on average, a significantly higher risk of breast cancer mortality but lower risk of colorectal cancer mortality was seen among women using HT compared with never users. There were no evident associations between HT and other causes of death. In summary, this resulted in no association for all-cause mortality. The development in mortality estimates during follow up diverged over time with the lower colorectal and higher breast cancer mortality only becoming evident after 15 years, while the initially lower CVD mortality dissipated.
Strength and limitations
This was a large, population-based cohort with long and almost complete (99.6%) follow up on mortality outcomes and with detailed and validated information on exposures and potential confounders. Furthermore, data on hormone use were collected before the dramatic drop seen after WHI results became official in 2002, and as most of the participants were well past menopause in 2002 [median age at end of 2002 was 63.1 years (5-95% range 57.2-71.1)], they should be largely unaffected by this. The major limitations include the observational nature of the data and hence the possible influence of residual confounding. 'Healthy users' selection is also of concern. To minimise this, we divided hormone use into current and previous use. Furthermore, we saw no difference in the associations for current users, who had recently initiated HT, and those with a longer interval between HT initiation and baseline (data not shown). Nevertheless, selection is unavoidably introduced when excluding women with morbidities relevant for the outcomes, and when susceptible women dying before potential recruitment could not be included. This is most likely to bias the associations towards the null-hypothesis. Information on brand names was not given by 11.6% (1021/8771) of the current hormone users. In addition, most women in the cohort took HT as oral medication, which hindered meaningful comparisons of different routes of administration. Finally, a major limitation is the single point measurement of hormone use, rendering changes in use after baseline unknown. This might introduce some exposure misclassification, especially if women switched between treatments. Some misclassification of cause of death also cannot be excluded; however, such misclassification is believed to be minimal 22 and would only influence the cause-specific estimates and not the overall mortality measure.
Interpretation
Despite the complex risk profile of HT reported from both major randomised trials and observational studies, when considering the aggregate effect of hormone use without consideration to specific subgroups of treatment or participants, the overall null effect on mortality found in this study concurs with most previous studies. 9, 23, 24 In contrast, a meta-analysis of studies of only younger women (< 60 years) including those in the young age strata in the WHI trial (50-59 years) found an overall reduced mortality among women taking HT, 25 primarily attributed to reductions in CVD mortality. 26 In the present cohort, which by these definitions consists mostly of younger women (median age at entry 56.2 years), a lower CVD mortality was only seen initially (after 5 years of follow up); however, no difference in overall mortality was observed. Part of the reason for this difference might be a different disease distribution; in this cohort, breast cancer comprised 36.3% (1996/5503) of all cancers, which is higher than the estimated European average of 28.8%, 27 and the higher mortality from breast cancer would counter the lower mortality seen from other causes. The substantially longer follow up in this study allowed for better estimation of mortality from postmenopausal breast cancer, which is generally more slowly progressing than other *Events = deaths. **Adjusted for age, alcohol, smoking, body mass index, physical activity and level of education. Table 3 . Hazard ratios and 95% confidence intervals for the associations between hormone therapy and selected cause-specific mortality cancers. In addition, a particularly prolonged recurrence pattern is seen among receptor-positive breast cancer, 28 which is also more common in women with previous HT use. [29] [30] [31] In this cohort, the median time (independent of exposure status) between breast cancer diagnosis and death was 1673 days (5-95%: 175-4969 days). Indeed, when looking more closely at the development in mortality estimates during follow up, a pattern of initially lower CVD mortality, which then dissipated during additional follow up, was evident, whereas the difference in cancer mortalities found to be associated with HT only became clear after much longer follow up.
The WHI combination trial also found a borderline significant increase in breast cancer mortality (HR 1.44, 95% CI 0.97-2.15). 9 However, paradoxically, a lower breast cancer-specific mortality was seen among women in the estrogen alone trial (HR 0.55, 95% CI 0.22-0.92; based on 63 deaths). 9 A potential explanation for this finding has been suggested to be different effects on breast cancer detection, which seems to be hindered among women on combined therapy but not among those on estrogen alone, 32 but the exact mechanisms behind this observation remain undetermined. 33 Hormone therapy use has been associated with a lower colorectal cancer incidence in both intervention and observational studies. A recent meta-analysis found an overall significantly lower risk of colorectal cancer for both types of hormone use (summary HR 0.83, 95% CI 0.79-0.88) and no differences depending on type or duration. 34 In the WHI, because the reduced colorectal cancer incidence did not translate into reduced colorectal cancer mortality, 35 it was interpreted as diagnostic delay rather than a clinically meaningful benefit of HT for preventing colorectal cancer. 36 Observational studies evaluating HT as chemoprevention published after the WHI all reported lower colorectal cancer risk similar to ours. 37 Worth noting is that most of these studies found the strongest association after longer duration of use, whereas short-term use did not seem to have long-lasting effects, just as was suggested in the WHI, 7 and hence possibly the reason for this discrepancy. However, it cannot be excluded that a differential selection of less susceptible women over time, at least in part, explains why the hazard ratios diminish with prolonged follow up rather than a truly preventive effect of HT being the cause. 13 The weak associations reported between HT and lung cancer mortality were based primarily on the results from WHI, 10 which found an increased risk of lung cancer death in women on combined therapy after 8 years of cumulative follow up [based on 73 deaths (intervention) versus 40 deaths (placebo)] 38 but attenuated with additional follow up. 39 No such association was found in this study despite a substantially larger number of lung cancer-related deaths (n = 576) and much longer follow up. Due to limited number of ovarian cancer deaths, the power to study the association between hormone use and ovarian cancer mortality was insufficient, which was also the case for other less common causes of death such as those related to neurological and psychiatric disorders, which have been suggested in early studies. 40 
Conclusion
As several previous studies have indicated, this long-term follow-up study confirmed that taking hormones during menopause was not significantly associated with overall mortality among middle-aged women. Investigating causespecific mortality and development in estimates during follow up revealed differential associations in both causes of death and time-specific associations with a slightly higher breast cancer mortality opposed by lower colorectal cancer mortality in the long term, and lower CVD mortality mainly in the short term. This divergent mortality pattern underlines the importance of carefully considering individual risks when making decisions onHT.
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